echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Zai Lab's Nirapali ovarian cancer first-line maintenance treatment indication approved in Hong Kong, China

    Zai Lab's Nirapali ovarian cancer first-line maintenance treatment indication approved in Hong Kong, China

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 25, Zai Lab announced that the Hong Kong Department of Health had approved the registration application of Ziller® (Nilapali) for the modification of registered pharmaceutical products for adult patients with advanced high-grade serous epithelial ovarian cancer to treat first-line platinum-containing products.
    Maintenance treatment after chemotherapy has achieved complete remission or partial remission
    .

    Zele® is an oral poly(ADP-ribose) polymerase (PARP) inhibitor once a day
    .


    Unlike other PARP inhibitors that have been approved in Hong Kong, Zele® does not require BRCA mutation or other biomarker testing before medication


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.